<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153115">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02007590</url>
  </required_header>
  <id_info>
    <org_study_id>13.LO.1124</org_study_id>
    <nct_id>NCT02007590</nct_id>
  </id_info>
  <brief_title>Aerosure and Six Minute Walk Distance in Severe COPD</brief_title>
  <acronym>ACCORD</acronym>
  <official_title>Does High-frequency Airflow Oscillation, Delivered Using Aerosure, Increase Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actegy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actegy Ltd.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>United Kingdom: National Institute for Health Research</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether high frequency airflow oscillation (HFAO), delivered using Aerosure,
      increases six minute walk distance (6MWD) and reduces exertional breathlessness in patients
      with severe chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Six minute walk distance (6MWD)</measure>
    <time_frame>up to 6 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>end-6MWD Borg breathlessness</measure>
    <time_frame>after 6 minute walk test</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial oxygen saturation (SpO2)</measure>
    <time_frame>At start of 6 minute walk test and after every 1 minute</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Inspiratory capacity (IC)</measure>
    <time_frame>At end of 6 minute walk test</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Aerosure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aerosure</intervention_name>
    <arm_group_label>Aerosure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <arm_group_label>Aerosure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable severe COPD (FEV1 &lt; 50% predicted)

          -  Modified MRC dyspnoea score 2 or greater

          -  At least 10 pack year smoking history

          -  Able to mobilise independently

        Exclusion Criteria:

          -  Contraindications to spirometry [1]

          -  Contraindications to clinical exercise testing [2]

          -  Contraindications to HFAO (see section A.6.3b))

          -  Resting SpO2&gt;88% on air or on patient's usual oxygen prescription

          -  Systolic arterial blood pressure (ABP) &gt;200mmHg, diastolic ABP &gt;100 mmHg

               1. Cooper, B.G., An update on contraindications for lung function testing. Thorax,
                  2010.

               2. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am. J. Respir. Crit.
                  Care Med., 2003. 167(2): p. 211-277.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Moxham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerrard Rafferty</last_name>
    <email>gerrard.rafferty@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles C Reilly</last_name>
    <email>charles.c.reilly@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College Hospital, Bessemer Road, Denmark Hill</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerrard Rafferty, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
